Stock Information
Bicara Therapeutics Inc (BCAX)
Ticker Symbol: BCAX
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $1,774.16 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): -2.7717
Revenue (TTM): $0.00 M
Dividend Yield: N/A%
ROE: -35.89%
Latest News
-
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
Wed, Aug 12, 2026 2:23 PM
-
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33
Wed, Aug 12, 2026 12:02 PM
-
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39
Wed, Aug 12, 2026 11:46 AM
-
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Wed, Aug 12, 2026 11:11 AM
-
Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
Wed, Aug 12, 2026 9:17 AM
-
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Wed, Aug 12, 2026 8:34 AM
-
Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23
Wed, Aug 12, 2026 8:22 AM
-
BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39
Wed, Aug 12, 2026 5:37 AM
-
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Tue, Aug 11, 2026 11:57 AM
-
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate
Tue, Aug 11, 2026 7:30 AM
Key Financials
Financial data not available
